Fluorescence Lifetime Imaging in Stargardt Disease: Potential Marker for Disease Progression

Dysli, Chantal; Wolf, Sebastian; Hatz, Katja; Zinkernagel, Martin S.

doi:10.1167/iovs.15-18033

Cited by 89 publications

(105 citation statements)

References 30 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While AMD patients display significantly shorter lifetime values in the border zones in comparison to the central atrophic lesion, lifetime values detected in STGD were similar throughout the atrophic lesion. Similar results have recently been described by Dysli et al [16][17][18]. Although the aforementioned study analyzed data from STGD and AMD patients separately, the outcomes are in good accordance.…”

Section: Discussionsupporting

confidence: 88%

“…The fluorescence lifetime represents the time span a natural retinal fluorophore spends upon excitation with a blue laser light at a higher energy level before returning to its ground state under the emission of autofluorescence. FLIO has been used previously to assess autofluorescence lifetime patterns independently in both AMD and STGD [16][17][18][19]. The aim of this study was to quantify autofluorescence lifetime patterns and to identify differences between atrophy secondary to STGD and AMD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fluorescence Lifetime Patterns of Retinal Pigment Epithelium Atrophy in Patients with Stargardt Disease and Age-Related Macular Degeneration

et al. 2019

Self Cite

View full text Add to dashboard Cite

Purpose: To investigate whether autofluorescence lifetime patterns within retinal pigment epithelium (RPE) atrophy differ between age-related macular degeneration (AMD) and Stargardt disease (STGD). Methods: Mean retinal autofluorescence lifetimes were measured in a short and a long spectral channel (SSC: 498-560 nm; LSC: 560-720 nm). Mean retinal fluorescence lifetimes were analyzed with corresponding clinical features, fundus images, fundus autofluorescence intensity images, and optical coherence tomography. Mean fluorescence lifetime values of atrophic areas were compared between the two cohorts and within the same patient to adjacent nonatrophic regions. Results: Mean fluorescence lifetimes within areas with RPE atrophy of 13 patients with STGD (mean age ± SEM 43.7 ± 5 years) and 30 patients with geographic atrophy (mean age: 78 ± 2 years) were analyzed and compared to age-matched healthy participants. The mean area of RPE atrophy in STGD and AMD was 6.6 ± 2.3 mm 2 (range: 0.66-33.17 mm 2 ) and 17.5 ± 3.8 mm 2 (range: 0.58-50.02 mm 2 ), respectively. In patients with AMD, atrophic areas revealed significantly longer mean fluorescence lifetime values as compared with patients with STGD (SSC: 997 ± 60 vs. 363 ± 26 ps; LSC: 880 ± 46 vs. 393 ± 23 ps; p < 0.0001). Conclusions: This study established that RPE atrophy in patients secondary to STGD and AMD display distinctive mean fluorescence lifetime characteristics. As retinal fluorescence lifetimes within areas of RPE atrophy were significantly longer in AMD patients, the analysis of specific lifetime patterns may provide additional insight into the disease processes and the pathogenetic mechanisms in the development of atrophic patches in AMD and STGD.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Fluorescence Lifetime Patterns of Retinal Pigment Epithelium Atrophy in Patients with Stargardt Disease and Age-Related Macular Degeneration

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…), in Stargadt disease (Dysli et al. ,b) and in the age‐related macular degeneration (Schweitzer ; Schweitzer et al. ) as well as its late form, geographic atrophy (Dysli et al.…”

Section: Introductionmentioning

confidence: 99%

Monitoring macular pigment changes in macular holes using fluorescence lifetime imaging ophthalmoscopy

Sauer

Peters

Schmidt

et al. 2016

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Dysli et al 37 investigated the potential prognostic markers of Stargardt disease (STGD) progression using FLIO. As shown in Fig.…”

Section: Eye Diseasesmentioning

confidence: 99%

Applications of fluorescence lifetime imaging in clinical medicine

Wang

Zheng

Zhao

et al. 2017

J. Innov. Opt. Health Sci.

View full text Add to dashboard Cite

Fluorescence lifetime is not only associated with the molecular structure of fluorophores, but also strongly depends on the environment around them, which allows fluorescence lifetime imaging microscopy (FLIM) to be used as a tool for precise measurement of the cell or tissue microenvironment. This review introduces the basic principle of fluorescence lifetime imaging technology and its application in clinical medicine, including research and diagnosis of diseases in skin, brain, eyes, mouth, bone, blood vessels and cavity organs, and drug evaluation. As a noninvasive, nontoxic and nonionizing radiation technique, FLIM demonstrates excellent performance with high sensitivity and specificity, which allows to determine precise position of the lesion and, thus, has good potential for application in biomedical research and clinical diagnosis.

show abstract

Fluorescence Lifetime Imaging in Stargardt Disease: Potential Marker for Disease Progression

Cited by 89 publications

References 30 publications

Fluorescence Lifetime Patterns of Retinal Pigment Epithelium Atrophy in Patients with Stargardt Disease and Age-Related Macular Degeneration

Fluorescence Lifetime Patterns of Retinal Pigment Epithelium Atrophy in Patients with Stargardt Disease and Age-Related Macular Degeneration

Monitoring macular pigment changes in macular holes using fluorescence lifetime imaging ophthalmoscopy

Applications of fluorescence lifetime imaging in clinical medicine

Contact Info

Product

Resources

About